Qalsody is one step closer to being covered by public Canadian healthcare systems when used to treat adults with ALS with ...

Parkinson's disease (PD) is an age-related, progressive, neurodegenerative condition, caused by loss of dopamine-producing ...

Kenai Therapeutics has dosed the first patient in its multi-centre Phase I REPLACE trial evaluating the allogeneic neuron ...

If you’ve been sidelined by an accident or surgery, occupational therapy (OT) is a valuable resource to help you return to ...

Determining which patients should receive the treatment will still require individual risk-benefit assessments, experts say.

The European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) has recommended granting ...

Kids and teenagers with spinal muscular atrophy had more mobility after receiving a single-dose gene replacement therapy, ...

The U.S. Food and Drug Administration has approved Itvisma (onasemnogene abeparvovec-brve) for the treatment of spinal ...

A single-dose gene replacement therapy is found to improve movement ability in children over 2 years of age and teenagers with spinal muscular atrophy, according to research published in Nature ...

There is improvement in upper-extremity function in children with perinatal stroke and UCP that receive a patient-centered intensive motor learning intervention. A patient-centered intensive motor ...

Doctors are turning to a new form of therapy to help stroke survivors regain mobility in their arms and hands, offering new hope for those facing long-term disability. Strokes remain one of the ...

Developed by Sarepta Therapeutics, Elevidys is a one-time, intravenous treatment that uses adeno-associated virus (AAV) technology to deliver a gene designed to produce a shortened form of the ...